Comparative Retroviral Epigenomics
Comparative Retroviral Epigenomics
批准号:
10115417
负责人:
Sarah Adrianne LaMere
金额:
$6.13万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-03-15 至 2023-06-30
关键词:
AddressAnimal ModelAnimal WelfareAreaAttentionBioinformaticsBiometryBrainCellsChromatinClinicalCollaborationsComparative StudyComplementDNAData AnalysesDevelopmentEpigenetic ProcessEthicsEvaluationExposure toFundingHIVHIV InfectionsHIV-1HumanImmune systemIn VitroInfectionInstitutionKnowledgeMacacaMedicineMentorsMethodsModelingModificationPeripheralPersonsPharmaceutical PreparationsPlayProceduresProvirusesPublishingRNARecordsReportingResearchResearch DesignResearch PersonnelRetrovirologyRoleSIVSamplingStatistical MethodsT-LymphocyteTechniquesTechnologyTestingTimeTissuesTrainingUnited States National Institutes of HealthVirusantiretroviral therapycareer developmentcomparativeeffective therapyepigenetic markerepigenomicsexperimental studylatent HIV reservoirnext generation sequencingnonhuman primatetargeted treatmenttherapeutic targettrial designviral rebound
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
Despite the successful development of antiretroviral therapies (ART), the long-awaited cure for HIV has still not
been discovered. The virus integrates into DNA of tissues throughout the body and becomes latent after
institution of ART. Persons receiving ART cannot discontinue their medications, as in most cases the virus will
simply rebound upon ART cessation. One approach to finding a cure is to eliminate the reservoir by bringing
the virus out of latency so that infected cells might be killed by ART or the host immune system. Epigenetic
mechanisms are believed to play an important role in retroviral latency, yet little is known about the epigenetic
markers associated with the latent reservoir for HIV. Surprisingly, even less has been published for SIV, where
access to tissues and time lines of infection are better characterized and controlled. While SIV-infected
macaques serve as a model for human HIV infection, there is no knowledge of whether SIV and HIV
epigenetics have any similarity. To develop successful therapeutics that target epigenetic mechanisms of HIV
latency, we must first identify these mechanisms and whether animal models will be suitable to test them.
The proposed project will characterize the proportion of proviruses located in open chromatin and containing
repressive epigenetic marks both during ART and after discontinuation of ART in HIV-infected humans and
SIV-infected macaques. Further, I will use these parameters to evaluate the association with the size of the
reservoir, cell-associated RNA, and viral rebound after ART cessation in both peripheral T cells and brain,
which is a poorly characterized reservoir tissue. These studies will allow me to conclude what role repressive
epigenetic marks play in proviral latency, and whether these mechanisms differ between tissues, and species.
Importantly, this project will support my development as an independent researcher with expertise in clinical
retroviral epigenetics and comparative research. The proposed training will provide me with exposure to trial
design and analysis methods, including biostatistics and bioinformatics. These methods are critical to my
career development, as we are now heavily reliant on next-generation sequencing technologies, and the
comparative studies I wish to pursue will require an understanding of statistical methods for study design and
data analysis. Finally, this project will build upon my background in comparative medicine, retrovirology, and
epigenetics. I will receive training in 1) clinical epigenetics techniques 2) biostatistics and bioinformatics 3) non-
human primate (NHP) procedures and NHP animal welfare 4) ethical conduct of HIV research and 5)
professional development, including grantsmanship, building collaborations, and reporting research findings.
My mentoring team includes an excellent track records in all proposed areas of training, including retrovirology,
epigenetics, biostatistics, bioinformatics, and non-human primate SIV research. This proposal builds upon
previous NIH funded research and complements current NIH funded projects.
Project Summary/Abstract Page 6
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Comparative Retroviral Epigenomics
-
批准号:10836287
-
项目类别:
-
资助金额:$12.26万
-
财政年份:2023
-
负责人:Sarah Adrianne LaMere
-
依托单位:
The impact of proviral epigenetics on HIV-1 rebound
-
批准号:10258541
-
项目类别:
-
资助金额:$23.68万
-
财政年份:2021
-
负责人:Sarah Adrianne LaMere
-
依托单位:
The impact of proviral epigenetics on HIV-1 rebound
-
批准号:10375596
-
项目类别:
-
资助金额:$19.75万
-
财政年份:2021
-
负责人:Sarah Adrianne LaMere
-
依托单位:
Comparative Retroviral Epigenomics
-
批准号:10199782
-
项目类别:
-
资助金额:$12.26万
-
财政年份:2018
-
负责人:Sarah Adrianne LaMere
-
依托单位:
Comparative Retroviral Epigenomics
-
批准号:10430170
-
项目类别:
-
资助金额:$12.26万
-
财政年份:2018
-
负责人:Sarah Adrianne LaMere
-
依托单位:
海外基金